1. In Vivo
  2. >>Business Strategy

Bard's Gamble on Restructuring

Troubled with severe price pressures, Bard undertakes a major restructuring.

The last several years haven’t been pretty ones at CR Bard. The USCI scandal not only hurt the company’s image, it effectively took Bard out of the high-margin angioplasty market where the company was once the leader. And while it has remained strong in its core hospital supply business, that market itself has been subject to severe price and margin pressures brought on by hospital group purchasing and managed care.

Earlier this year, Bard launched a corporate marketing effort, but that apparently wasn’t enough. In late November, the company undertook...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.